Literature DB >> 16005563

Risk factors for mucosal prostatic urethral involvement in superficial transitional cell carcinoma of the bladder.

M Ugur Mungan1, A Erdem Canda, Emre Tuzel, Kutsal Yorukoglu, Ziya Kirkali.   

Abstract

OBJECTIVE: Prostatic transitional cell carcinoma (TCC) may involve urethral mucosa, ducts, acini and stroma of the gland. In this study, we evaluated the risk factors for mucosal prostatic urethral (PU) involvement in superficial TCC of the bladder.
METHODS: The data of 340 consecutive male patients with the diagnosis of primary superficial TCC of the bladder who were treated at our institution were reviewed. Median age of the patients was 64 years and median follow-up was 66 months. The impact of pathological stage, grade, tumour multiplicity and presence of carcinoma in situ (CIS) on mucosal PU involvement were evaluated.
RESULTS: Twenty one patients (6.2%) had mucosal involvement of the PU and concomitant multifocal TCC of the bladder. Of those, 12 patients (3.5%) had macroscopic mucosal involvement of the PU while the other 9 patients (2.7%) had microscopic tumour. Increased pathological stage, grade and tumour multiplicity were found to be risk factors for mucosal PU involvement in patients with superficial bladder cancer. Multivariate analysis showed that only the tumour multiplicity was found to be an independent risk factor for mucosal PU involvement by TCC (p=0.001).
CONCLUSIONS: The incidence of mucosal PU involvement increases as the stage, grade and number of tumours increase in patients with superficial TCC of the bladder. We recommend PU sampling particularly in patients with multiple bladder tumours which may have an impact on further management of these patients.

Entities:  

Mesh:

Year:  2005        PMID: 16005563     DOI: 10.1016/j.eururo.2005.05.021

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  11 in total

1.  Best practice in the treatment of nonmuscle invasive bladder cancer.

Authors:  Anastasios Anastasiadis; Theo M de Reijke
Journal:  Ther Adv Urol       Date:  2012-02

2.  [Tumors of the urinary system. Current and old problems].

Authors:  S Minner; G Sauter
Journal:  Pathologe       Date:  2009-12       Impact factor: 1.011

3.  Saudi Oncology Society clinical management guidelines for urinary bladder cancer.

Authors:  Khaled Al Othman; Shouki Bazarbashi; Khalid Balaraj; Mohamed Al Otaibi; Baher Kamal; Ibraheem Al Oraifi; Eyad Al Saeed; Khalid Al Gamdi; Ali Jubran; Ahmad Salah; Jalal Al Shareef; Jamal Zekri
Journal:  Urol Ann       Date:  2011-03

4.  Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015.

Authors:  Wassim Kassouf; Armen Aprikian; Peter Black; Girish Kulkarni; Jonathan Izawa; Libni Eapen; Adrian Fairey; Alan So; Scott North; Ricardo Rendon; Srikala S Sridhar; Tarik Alam; Fadi Brimo; Normand Blais; Chris Booth; Joseph Chin; Peter Chung; Darrel Drachenberg; Yves Fradet; Michael Jewett; Ron Moore; Chris Morash; Bobby Shayegan; Geoffrey Gotto; Neil Fleshner; Fred Saad; D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2016-02-08       Impact factor: 1.862

5.  Saudi oncology society and Saudi urology association combined clinical management guidelines for urothelial urinary bladder cancer.

Authors:  Mubarak Al-Mansour; Ahmad Saadeddin; Sultan Alkhateeb; Ashraf Abusamra; Danny Rabah; Mohammed Alotaibi; Esam Murshid; Abdullah Alsharm; Imran Ahmad; Khalid Alghamdi; Shouki Bazarbashi
Journal:  Urol Ann       Date:  2014-10

Review 6.  How do we manage high-grade T1 bladder cancer? Conservative or aggressive therapy?

Authors:  Seok Joong Yun; Seon-Kyu Kim; Wun-Jae Kim
Journal:  Investig Clin Urol       Date:  2016-06-10

Review 7.  The recurrence and progression risk after simultaneous endoscopic surgery of urothelial bladder tumour and benign prostatic hyperplasia: a systematic review and meta-analysis.

Authors:  Reza Sari Motlagh; Keiichiro Mori; Noriyoshi Miura; Fahad Quhal; Abdulmajeed Aydh; Ekaterina Laukhtina; Benjamin Pradere; Pierre I Karakiewicz; Dmitry V Enikeev; Marina Deuker; Shahrokh F Shariat
Journal:  BJU Int       Date:  2020-08-12       Impact factor: 5.588

Review 8.  Transurethral resection of bladder tumour (TURBT).

Authors:  Lawrence H C Kim; Manish I Patel
Journal:  Transl Androl Urol       Date:  2020-12

Review 9.  Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for urothelial cell carcinoma of the urinary bladder.

Authors:  Sultan Alkhateeb; Mubarak Al-Mansour; Mohammed Alotaibi; Ahmad Saadeddin; Ashraf Abusamra; Danny Rabah; Esam Murshid; Abdullah Alsharm; Imran Ahmad; Hussain Kushi; Abdullah Alghamdi; Khalid Alghamdi; Shouki Bazarbashi
Journal:  Urol Ann       Date:  2016 Apr-Jun

Review 10.  Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for urothelial cell carcinoma of the urinary bladder 2017.

Authors:  Hulayel Alharbi; Sultan Alkhateeb; Esam Murshid; Mohammed Alotaibi; Ashraf Abusamra; Danny Rabah; Mubarak Almansour; Abdullah Alghamdi; Ali Aljubran; Amin Eltigani; Hussein Alkushi; Imran Ahmed; Abdullah Alsharm; Shouki Bazarbashi
Journal:  Urol Ann       Date:  2018 Apr-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.